Bausch + Lomb (BLCO) said Wednesday it obtained European CE Mark approval for its LuxLife vision intraocular lens.
The LuxLife intraocular lens allow surgeons to treat the 79.5% of people with more than 0.5D of corneal astigmatism before cataract surgery, the company said.
The LuxLife intraocular lens will be commercially available in Europe in the coming weeks, Bausch + Lomb said.
The company's shares were rising 1% in recent trading.
Price: 11.03, Change: +0.13, Percent Change: +1.19
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。